The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of close of business last night, Monte Rosa Therapeutics Inc’s stock clocked out at $7.74, down -8.73% from its previous closing price of $8.48. In other words, the price has decreased by -$8.73 from its previous closing price. On the day, 0.88 million shares were traded. GLUE stock price reached its highest trading level at $8.63 during the session, while it also had its lowest trading level at $7.65.
Ratios:
To gain a deeper understanding of GLUE’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.03 and its Current Ratio is at 6.03. In the meantime, Its Debt-to-Equity ratio is 0.21 whereas as Long-Term Debt/Eq ratio is at 0.19.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wedbush on February 15, 2024, initiated with a Outperform rating and assigned the stock a target price of $11.
On January 03, 2023, Wells Fargo Upgraded its rating to Overweight which previously was Equal Weight but kept the price unchanged to $18.
On October 13, 2022, UBS started tracking the stock assigning a Buy rating and target price of $22.UBS initiated its Buy rating on October 13, 2022, with a $22 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Oct 28 ’24 when Versant Venture Capital VI, L. sold 89,990 shares for $9.66 per share. The transaction valued at 869,240 led to the insider holds 2,007,948 shares of the business.
Versant Venture Capital VI, L. sold 67,905 shares of GLUE for $621,801 on Oct 29 ’24. The 10% Owner now owns 1,573,453 shares after completing the transaction at $9.16 per share. On Oct 28 ’24, another insider, Wallace Owen B., who serves as the Officer of the company, bought 20,000 shares for $12.00 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GLUE now has a Market Capitalization of 475520032 and an Enterprise Value of 277027552. For the stock, the TTM Price-to-Sale (P/S) ratio is 28.99 while its Price-to-Book (P/B) ratio in mrq is 2.31. Its current Enterprise Value per Revenue stands at 18.499 whereas that against EBITDA is -2.288.
Stock Price History:
Over the past 52 weeks, GLUE has reached a high of $12.40, while it has fallen to a 52-week low of $2.91. The 50-Day Moving Average of the stock is 18.31%, while the 200-Day Moving Average is calculated to be 39.10%.
Shares Statistics:
It appears that GLUE traded 2.12M shares on average per day over the past three months and 1352570 shares per day over the past ten days. A total of 50.14M shares are outstanding, with a floating share count of 46.18M. Insiders hold about 24.83% of the company’s shares, while institutions hold 68.56% stake in the company. Shares short for GLUE as of 1730332800 were 7837789 with a Short Ratio of 3.70, compared to 1727654400 on 4377009. Therefore, it implies a Short% of Shares Outstanding of 7837789 and a Short% of Float of 23.35.
